TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23271103

Group type: EXPERIMENTAL
Intervention: Insulin levels greater than 15 µU/mL
Number of subjects: 160

Group type: COMPARATOR
Intervention: Insulin levels of 5 µU/mL to 15 µU/mL
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 160

Group type: COMPARATOR
Intervention: Nonsurvivors
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sepsis patients
Number of subjects: 160
Study: 20622608

Group type: EXPERIMENTAL
Intervention: NIRS-derived StO2
Number of subjects: 147
Study: 18274807

Group type: COMPARATOR
Intervention: Volumetric MRI measures (T(1)-weighted scans)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cognitive tests including MMSE, AD Assessment Scale-Cognitive Subscale, Disability Assessment for Dementia, AD Cooperative Study-Clinical Global Impression of Change, Clinical Dementia Rating
Number of subjects: 52
Study: 16183735

Group type: EXPERIMENTAL
Intervention: Direct observation by health facility workers
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Direct observation by community health workers
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Direct observation by family members
Number of subjects: 32

Group type: COMPARATOR
Intervention: Self-administered treatment (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: In-depth interviews with patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall TB care approach
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Provider attitudes
Number of subjects: 32
Study: 12932604

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day for 8 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11383021

Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Resin composite
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 49
Study: 8667129

Group type: EXPERIMENTAL
Intervention: Coronal scaling (CS)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Root planing (RP)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Modified Widman surgery (MW)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Flap with osseous surgery (FO)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Supportive periodontal treatment (SPT)
Number of subjects: 82
Study: 1297876

Group type: EXPERIMENTAL
Intervention: Cardil, 240‐360 mg/day
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cordafen, 30‐60 mg/day
Number of subjects: 74
Study: 30908408

Group type: EXPERIMENTAL
Intervention: Text messaging weight loss intervention
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (website only)
Number of subjects: 188
Study: 28039317

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon β‐1a (sc IFN β‐1a) three times weekly (tiw)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon β‐1a (sc IFN β‐1a) once weekly (qw)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Delayed treatment (DT)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon β‐1a (sc IFN β‐1a) tiw
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon β‐1a (sc IFN β‐1a) qw and tiw
Number of subjects: 402
Study: 25559065

Group type: EXPERIMENTAL
Intervention: BCQB 180μg alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: BCQB 180μg co-administered with paroxetine 20mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: BCQB 180μg in Study B (Group A)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Roxithromycin 150mg in Study B (Group B)
Number of subjects: 33
Study: 23817631

Group type: EXPERIMENTAL
Intervention: Biological treatment with infliximab
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional treatment with sulfasalazine plus hydroxychloroquine
Number of subjects: 204
Study: 21062337

Group type: EXPERIMENTAL
Intervention: Scalloped implant group (20 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flat implant group (20 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 19389107

Group type: EXPERIMENTAL
Intervention: Adjuvant ALA-PDT after CO(2) laser ablation (n=84)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Adjuvant placebo-PDT after CO(2) laser ablation (n=91)
Number of subjects: 175
Study: 18821458

Group type: EXPERIMENTAL
Intervention: Behavioral Therapy for Depression in Drug Dependence (BTDD)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Structured relaxation intervention (REL)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both BTDD and REL
Number of subjects: 38
Study: 16505753

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Sedation (PCS) with propofol (20-mg boluses)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard sedation (control group) with continuous infusion of propofol
Number of subjects: 72
Study: 12443589

Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound scan (invited group, n=33839)
Number of subjects: 67800

Group type: COMPARATOR
Intervention: Control group (n=33961, no screening)
Number of subjects: 67800

Group type: EXPERIMENTAL
Intervention: Attended screening (subgroup of invited group)
Number of subjects: 67800

Group type: EXPERIMENTAL
Intervention: Elective surgery for an aneurysm
Number of subjects: 67800

Group type: EXPERIMENTAL
Intervention: Emergency surgery for an aneurysm
Number of subjects: 67800
Study: 10611625

Group type: EXPERIMENTAL
Intervention: Fresenius AS104
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fenwal Amicus
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: COBE Spectra Version 7 (Turbo)
Number of subjects: 20

Group type: COMPARATOR
Intervention: COBE Spectra Version 5 (V5‐LRS)
Number of subjects: 20
Study: 7494655

Group type: EXPERIMENTAL
Intervention: Sucrose 50% (2 mL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (distilled water, 2 mL)
Number of subjects: 16
Study: 1702944

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Number of subjects: 60
Study: 7049296

Group type: EXPERIMENTAL
Intervention: Supportive home visiting from community psychiatric nurses
Number of subjects: 71

Group type: COMPARATOR
Intervention: Routine psychiatric out‐patient care
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Community psychiatric nursing
Number of subjects: 71
Study: 31995035

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study: 30447348

Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution 10% for about 1 min
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (no vaginal cleansing)
Number of subjects: 226
Study: 29058628

Group type: EXPERIMENTAL
Intervention: Strength training (two sessions per week for one hour)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lifestyle change advice (control group)
Number of subjects: 40
Study: 25520214

Group type: EXPERIMENTAL
Intervention: Oral glucose administration
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 32
Study: 24369366

Group type: EXPERIMENTAL
Intervention: Fast ForWord® exercises in a game‐like format, 30 sessions
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 81
Study: 22314101

Group type: EXPERIMENTAL
Intervention: Korean red ginseng extract (9 capsules per day for 3 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (9 capsules per day for 3 months)
Number of subjects: 100
Study: 19413910

Group type: EXPERIMENTAL
Intervention: Walking School Bus (WSB) program
Number of subjects: 653

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 653
Study: 17331082

Group type: EXPERIMENTAL
Intervention: Combined diet and exercise intervention
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Diet alone
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Exercise alone
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control
Number of subjects: 137
Study: 14698828

Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) after dilatation and curettage
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) after administration of danazol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) after administration of goserelin acetate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Goserelin group
Number of subjects: 90
Study: 11556125

Group type: EXPERIMENTAL
Intervention: Enteric-coated pellets containing 75 mg diclofenac sodium (A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Enteric-coated tablet with 50 mg diclofenac sodium (B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Capsule containing 140 mg diclofenac resinate (C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dispersible tablet containing 46.5 mg diclofenac acid (D)
Number of subjects: 16
Study: 10021877

Group type: EXPERIMENTAL
Intervention: Splenomegaly due to portal hypertension (17 patients)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Splenomegaly due to myeloproliferative disease (7 patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (25 patients without splenomegaly)
Number of subjects: 24
Study: 7798613

Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde 1%
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde 0.5%
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde 0.1%
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde 0.05%
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde (0.5%, 0.1%, 0.05%)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde
Number of subjects: 229
Study: 3046408

Group type: EXPERIMENTAL
Intervention: Levocabastine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 44
Study: 27402729

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive task
Number of subjects: 0
Study: 27556896

Group type: EXPERIMENTAL
Intervention: Nasal saline irrigations (NSI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-irrigation
Number of subjects: 0
Study: 25622123

Group type: EXPERIMENTAL
Intervention: 380 mg naltrexone injection + weekly psychotherapy for 4 weeks
Number of subjects: 22
Study: 23514288

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine
Number of subjects: 447

Group type: COMPARATOR
Intervention: Rabies vaccine (control)
Number of subjects: 447
Study: 20890238

Group type: EXPERIMENTAL
Intervention: Brimonidine (0.15%)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 244
Study: 18353201

Group type: EXPERIMENTAL
Intervention: Opalescence PF 10% (OPA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 50
Study: 17093898

Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy)
Number of subjects: 34
Study: 12022462

Group type: EXPERIMENTAL
Intervention: 50% AgNO3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (water soaking)
Number of subjects: 0
Study: 10484048

Group type: EXPERIMENTAL
Intervention: D + T (Diet + Troglitazone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S + T (Sulfonylurea + Troglitazone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (only diet therapy)
Number of subjects: 0
Study: 8564488

Group type: EXPERIMENTAL
Intervention: Low molecular mass heparin (LMMH) (70 anti‐Xa units/kg b.w.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low molecular mass heparin (LMMH)
Number of subjects: 18
Study: 1769130

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (2 mg/kg p.o.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7094779

Group type: EXPERIMENTAL
Intervention: Occult blood test in stool
Number of subjects: 48000

Group type: EXPERIMENTAL
Intervention: Complete colonic workup including colonoscopy
Number of subjects: 48000

Group type: EXPERIMENTAL
Intervention: Air‐contrast barium‐enema examination
Number of subjects: 48000

Group type: EXPERIMENTAL
Intervention: Dukes' A stage
Number of subjects: 48000

Group type: EXPERIMENTAL
Intervention: Dukes' B stage
Number of subjects: 48000

Group type: EXPERIMENTAL
Intervention: Dukes' C stage
Number of subjects: 48000

Group type: EXPERIMENTAL
Intervention: Dukes' D stage
Number of subjects: 48000
Study: 30323055

Group type: EXPERIMENTAL
Intervention: Inhaled cannabis (100 mg dose)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No cannabis
Number of subjects: 45
Study: 26876657

Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 2148

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 2148

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 2148

Group type: EXPERIMENTAL
Intervention: Housing First (general)
Number of subjects: 2148
Study: 25693050

Group type: EXPERIMENTAL
Intervention: Intervention (SMS-based intervention)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 366
Study: 23748474

Group type: EXPERIMENTAL
Intervention: Phenobarbitone (PB) 10 mg/kg/day on day 1 followed by 5 mg/kg/day on days 2-5
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral glucose (control)
Number of subjects: 44
Study: 20946161

Group type: EXPERIMENTAL
Intervention: Sildenafil (flexible-dose of 25, 50, or 100 mg)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 176
Study: 18783652

Group type: EXPERIMENTAL
Intervention: Intratumoral radiotracer administration (n=35)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Peritumoral radiotracer administration (n=45)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intratumoral radiotracer administration
Number of subjects: 80

Group type: COMPARATOR
Intervention: Peritumoral radiotracer administration
Number of subjects: 80
Study: 16815489

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 445
Study: 12823113

Group type: EXPERIMENTAL
Intervention: Symptoms of asthma
Number of subjects: 15706

Group type: EXPERIMENTAL
Intervention: Symptoms of allergic rhinitis
Number of subjects: 15706

Group type: EXPERIMENTAL
Intervention: Symptoms of atopic eczema
Number of subjects: 15706

Group type: EXPERIMENTAL
Intervention: Indices of diagnosis
Number of subjects: 15706

Group type: EXPERIMENTAL
Intervention: Indices of severity
Number of subjects: 15706
Study: 11120577

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2% ophthalmic solution
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 9372661

Group type: EXPERIMENTAL
Intervention: Lung-protective approach (LPA) with permissive hypercapnia (PHY), VT < 6 ml/kg, distending pressures above PEEP < 20 cm H2O, and PEEP 2 cm H2O above the lower inflection point on the static inspiratory P-V curve (P(FLEX))
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 48
Study: 8092801

Group type: EXPERIMENTAL
Intervention: Thyroid hormone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3894871

Group type: COMPARATOR
Intervention: 50 g of glucose (G)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 50 g of fructose (F)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sweet placebo (C)
Number of subjects: 8
Study: 30365984

Group type: EXPERIMENTAL
Intervention: EndoRings
Number of subjects: 927

Group type: COMPARATOR
Intervention: standard
Number of subjects: 927
Study: 28475473

Group type: EXPERIMENTAL
Intervention: Vitamin D supplement (50,000 units, one every fortnight for 8 weeks)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 26306589

Group type: EXPERIMENTAL
Intervention: Urinary Magnesium to Creatinine ratio (Mg/Cr)
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: Urinary Calcium to Creatinine ratio (Ca/Cr)
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: Urinary Phosphorus to Creatinine ratio (P/Cr)
Number of subjects: 1403
Study: 24767623

Group type: EXPERIMENTAL
Intervention: Supraliminal training
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Masked training
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control training
Number of subjects: 56
Study: 22429479

Group type: EXPERIMENTAL
Intervention: Fluoxetine administration
Number of subjects: 21
Study: 20963997

Group type: EXPERIMENTAL
Intervention: Natural drainage
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine negative pressure drainage
Number of subjects: 50
Study: 18080725

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 40
Study: 16157604

Group type: EXPERIMENTAL
Intervention: Opt-in recruitment strategy
Number of subjects: 510

Group type: COMPARATOR
Intervention: Opt-out recruitment strategy
Number of subjects: 510
Study: 12841498

Group type: EXPERIMENTAL
Intervention: Mycobacterium w (immuvac) as adjuvant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination chemotherapy (cisplatin and etoposide) and radiotherapy (control group)
Number of subjects: 0
Study: 10823753

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (no ganciclovir)
Number of subjects: 92
Study: 8862741

Group type: EXPERIMENTAL
Intervention: Fluid and salt supplementation (0.1 g sodium chloride/kg body weight and 30 mL water/kg body weight) during hypokinesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Unsupplemented hypokinetic subjects (2.7 km/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects (14.0 km/d)
Number of subjects: 30
Study: 1284155

Group type: EXPERIMENTAL
Intervention: Gallopamil (0.4 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 24
Study: 3890508

Group type: EXPERIMENTAL
Intervention: Intravenous heparin followed by oral warfarin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 53
Study: 31393834

Group type: COMPARATOR
Intervention: s‐TDI measurements in SGA fetuses
Number of subjects: 120

Group type: COMPARATOR
Intervention: s‐TDI measurements in LO-FGR fetuses
Number of subjects: 120

Group type: COMPARATOR
Intervention: s‐TDI measurements in SGA and LO-FGR fetuses
Number of subjects: 120
Study: 29155001

Group type: EXPERIMENTAL
Intervention: Left‐sided iliac crest bone graft (ICBG) harvesting
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Right‐sided iliac crest bone graft (ICBG) harvesting
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-harvested side (internal control)
Number of subjects: 40
Study: 27163301

Group type: EXPERIMENTAL
Intervention: Quartile 4 (lowest muscle ratio)
Number of subjects: 2383

Group type: EXPERIMENTAL
Intervention: Arm and leg muscle mass to total body weight ratio
Number of subjects: 2383
Study: 24616451

Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low-fat diet (LFD)
Number of subjects: 29
Study: 20863395

Group type: EXPERIMENTAL
Intervention: Early intervention (multimodal approach including patient prompts, clinician prompts, outreach, low-literacy education tools)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 0
Study: 16236738

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus adjuvant chemotherapy (doxorubicin and cyclophosphamide followed by paclitaxel) for 52 weeks
Number of subjects: 394

Group type: COMPARATOR
Intervention: Control group (doxorubicin and cyclophosphamide followed by paclitaxel without trastuzumab)
Number of subjects: 394
Study: 12166560

Group type: EXPERIMENTAL
Intervention: Itraconazole and budesonide
Number of subjects: 37

Group type: COMPARATOR
Intervention: Itraconazole alone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (CF patients)
Number of subjects: 37
Study: 9784040

Group type: EXPERIMENTAL
Intervention: Terbinafine (125 or 250 mg/day) for 1 week
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Terbinafine (125 or 250 mg/day) for 2 weeks
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Terbinafine (125 or 250 mg/day) for 4 weeks
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (Griseofulvin or Ketoconazole not specified)
Number of subjects: 107
Study: 8112206

Group type: EXPERIMENTAL
Intervention: Fibrin injection (with adrenalin: n = 11; without adrenalin: n = 29)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Polidocanol injection (with adrenalin: n = 17; without adrenalin: n = 8)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Adrenalin injection alone (n = 15)
Number of subjects: 80
Study: 2468838

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Combination of Nifedipine and Metoprolol
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Nifedipine (in patients already on beta-blocker)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 515
Study: 11286323

Group type: EXPERIMENTAL
Intervention: tolterodine L‐tartrate ER 8 mg (2 x 4 mg capsules) with a standardised high‐fat breakfast
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: tolterodine L‐tartrate ER 8 mg (2 x 4 mg capsules) on an empty stomach
Number of subjects: 17

Group type: COMPARATOR
Intervention: tolterodine L‐tartrate IR 4 mg (2 x 2 mg tablets) administered in the fasting state
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Safety endpoints
Number of subjects: 17
Study: 31590154

Group type: EXPERIMENTAL
Intervention: Resistance exercise combined with aerobic or impact training for 3 to 6 months
Number of subjects: 152
Study: 30099530

Group type: EXPERIMENTAL
Intervention: Statin with a run-in period (test dose)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Statin without a run-in period (no test dose)
Number of subjects: 1000
Study: 26334255

Group type: EXPERIMENTAL
Intervention: SN2‐palmitate formula (n=57)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control formula (n=57)
Number of subjects: 171